All Releases
 |
SciClone Pharmaceuticals to Report Second Quarter 2010 Financial Results and Provide a Business Update on August 9
Jul 26, 2010
|
7.4 KB |
| |
FOSTER CITY, CA, Jul 26, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report second quarter 2010 financial results on Monday, August 9, 2010. SciClone will host a conference call to give a business and product update at 4:30 pm ET that day. The call will be hosted by Fri...
|
|
SciClone and Sigma-Tau Announce Final Data From Clinical Trial of ZADAXIN as H1N1 Vaccine Enhancer
Jun 30, 2010
|
12.0 KB |
| |
FOSTER CITY, CA, Jun 30, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A., announced final results from a clinical study evaluating the potential of ZADAXIN(R) (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria(R) from...
|
|
SciClone Pharmaceuticals to Present at Three Investor Conferences in June
Jun 3, 2010
|
7.2 KB |
| |
FOSTER CITY, CA, Jun 03, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at three upcoming investor conferences: Jefferies 2010 Global Life Sciences Conference, Needham Annual Healthcare Conference, and ThinkEquity Mid-Year Check up on Healthcare Conference. SciClone's ...
|
|
SciClone Provides Clinical Program Update for SCV-07 for the Prevention of Oral Mucositis in Patients With Advanced Head and Neck Cancer
May 17, 2010
|
13.2 KB |
| |
FOSTER CITY, CA, May 17, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced further topline results from the company's phase 2 proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer -- a painful and debil...
|
|
SciClone Pharmaceuticals to Present at Two Investor Conferences in May
May 10, 2010
|
7.1 KB |
| |
FOSTER CITY, CA, May 10, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: Rodman & Renshaw Annual London Investment China Conference, and the Oppenheimer Annual China Dragon Call Conference. SciClone's executives will present a corpo...
|
|
SciClone Reports Financial Results for the First Quarter of 2010
May 6, 2010
|
15.3 KB |
| |
FOSTER CITY, CA, May 06, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the first quarter of 2010. Revenues for the quarter grew 19% to $18.0 million compared with the same period last year. SciClone reported net income of $4.2 million, or $0.09 per share, compared wit...
|
|
SciClone Pharmaceuticals to Report First Quarter 2010 Results on May 6
Apr 26, 2010
|
7.3 KB |
| |
FOSTER CITY, CA, Apr 26, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report first quarter 2010 results on Thursday, May 6, 2010. SciClone will host a conference call to give a business and product update at 4:30 pm ET that day. The call will be hosted by Friedhelm Blobe...
|
|
SciClone Announces Topline Results From Phase 2 Clinical Trial of SCV-07 for Prevention of Oral Mucositis
Mar 30, 2010
|
11.8 KB |
| |
FOSTER CITY, CA, Mar 30, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced topline results from the company's phase 2 clinical trial of SCV-07 for the prevention of severe oral mucositis (OM) (World Health Organization, WHO scale, grades 3 to 4) -- a painful, debilitating, and costly toxicity...
|
|
ondansetron RapidFilm(TM) Approved in 16 European Countries
Mar 24, 2010
|
9.6 KB |
| |
FOSTER CITY, CA, Mar 24, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the European approval of ondansetron RapidFilm(TM), co-developed by APR Applied Pharma Research s.a. ("APR"), and Labtec GmbH and licensed to BioAlliance Pharma s.a. for European Union ("EU") countries. BioAlliance was...
|
|
SciClone Reports Financial Results for the Fourth Quarter and Year End 2009 and Provides Commercial and Pipeline Updates
Mar 2, 2010
|
19.1 KB |
| |
FOSTER CITY, CA, Mar 02, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the fourth quarter and year ended December 31, 2009. Revenues for the fourth quarter of 2009 grew to $18.1 million, or 18% compared to the fourth quarter of 2008. Net income for the fourth quarter of 2009 wa...
|
|
SciClone Pharmaceuticals to Present at Three Investor Conferences in March
Mar 1, 2010
|
7.2 KB |
| |
FOSTER CITY, CA, Mar 01, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at three upcoming investor conferences: Rodman & Renshaw Annual China Investment Conference, Cowen Healthcare Conference, and Roth Growth Stock Conference. SciClone's executives will present a corp...
|
|
SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results on March 2, 2010
Feb 18, 2010
|
8.7 KB |
| |
FOSTER CITY, Calif., Feb 18, 2010 (BUSINESS WIRE) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it
plans to report fourth quarter and year-end results for 2009 on Tuesday,
March 2, 2010. SciClone will host a conference call to give a business
and product update and guidance for 2010 at 4:30 pm ET that...
|
|
SciClone and Sigma-Tau Announce Additional Positive Results in Clinical Study Examining ZADAXIN's Ability to Enhance Response to H1N1 Vaccine
Feb 8, 2010
|
11.8 KB |
| |
FOSTER CITY, CA and ROME, Feb 08, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A., announced additional topline results in a clinical study evaluating the potential of ZADAXIN(R) (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vacci...
|
|
SciClone Pharmaceuticals to Present at BIO CEO & Investor Conference
Feb 2, 2010
|
6.7 KB |
| |
FOSTER CITY, CA, Feb 02, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will present a corporate overview and business update at the BIO CEO & Investor Conference 2010 on February 9, 2010 at 1:30 p.m. ET in New York City....
|
|
SciClone and Sigma-Tau Announce Positive Preliminary Results in Clinical Study Examining ZADAXIN'S Ability to Enhance Response to H1N1 Vaccine
Jan 12, 2010
|
11.9 KB |
| |
FOSTER CITY, CA and ROME, Jan 12, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A. have received initial topline results in a clinical study evaluating the potential of ZADAXIN(R) (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vacci...
|
|
SciClone Provides 2009 Financial Update and Initial 2010 Sales Revenue Guidance
Jan 11, 2010
|
8.6 KB |
| |
FOSTER CITY, CA, Jan 11, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its full year 2009 sales revenue, 2010 sales revenue guidance and its year-end cash position as follows:
-- For 2009, the company anticipates revenues of approximately $72.4
million (unaudited), a 34% incre...
|
|
SciClone Announces Commencement and Complete Enrollment of Clinical Study Examining ZADAXIN's Ability to Enhance the H1N1 Vaccine Led by European Partner, Sigma-Tau
Nov 30, 2009
|
11.8 KB |
| |
FOSTER CITY, CA, Nov 30, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
Rome-based development partner Sigma-Tau, S.p.A., has initiated a
pilot study in Italy to evaluate ZADAXIN's® (thymalfasin) ability
to enhance immune response to the MF59 adjuvanted H1N...
|
|
SciClone Announces Enrollment Completion in Phase 2 Oral Mucositis Trial of SCV-07
Nov 23, 2009
|
10.4 KB |
| |
FOSTER CITY, CA, Nov 23, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
patient enrollment is complete ahead of schedule for its phase 2
trial of SCV-07 -- a small molecule synthetic peptide with
immunomodulating properties -- for the treatment of severe oral
mucositis (OM) in patients with he...
|
|
SciClone Pharmaceuticals to Present at the Piper Jaffray Annual Healthcare Conference
Nov 23, 2009
|
6.1 KB |
| |
FOSTER CITY, CA, Nov 23, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
it will present at the upcoming Piper Jaffray Annual Healthcare
Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's
President and Chief Executive Officer, will present a corporate
overview and business update ...
|
|
SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings
Nov 12, 2009
|
10.7 KB |
| |
FOSTER CITY, CA, Nov 12, 2009 (MARKETWIRE via COMTEX) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced
presentations of multiple abstracts demonstrating SCV-07's anti-tumor
immunomodulating properties at two upcoming events: Cold Spring
Harbor Laboratory's Harnessing Immunity to Prevent and Treat Disease
meeting; and the America...
|
|
|
